Emergent Gets Contract Option With BARDA for Ebola Treatment

MT Newswires Live

01/14

Emergent BioSolutions (EBS) said Monday that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at about $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga.

Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus.

BARDA is part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.

The option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga, with a maximum value of $704 million, the company said.

Shares of Emergent BioSolutions fell past 5% in recent trading.

Price: 9.33, Change: -0.55, Percent Change: -5.57

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503532429"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503532429\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503532429?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 03:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503532429","market":"sg","top_or_hot":-1,"title":"Emergent Gets Contract Option With BARDA for Ebola Treatment","media":"MT Newswires Live","content":"<html><body><p> Emergent BioSolutions (EBS) said Monday that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at about $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga.</p><p>Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus.</p><p>BARDA is part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.</p><p>The option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga, with a maximum value of $704 million, the company said.</p><p>Shares of Emergent BioSolutions fell past 5% in recent trading.</p><p>Price: 9.33, Change: -0.55, Percent Change: -5.57</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent Gets Contract Option With BARDA for Ebola Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent Gets Contract Option With BARDA for Ebola Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-14 03:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Emergent BioSolutions (EBS) said Monday that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at about $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga.</p><p>Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus.</p><p>BARDA is part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.</p><p>The option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga, with a maximum value of $704 million, the company said.</p><p>Shares of Emergent BioSolutions fell past 5% in recent trading.</p><p>Price: 9.33, Change: -0.55, Percent Change: -5.57</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503532429","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503532429","pubTimestamp":1736796531,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Emergent BioSolutions  said Monday that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at about $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga.Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus.BARDA is part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.The option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga, with a maximum value of $704 million, the company said.Shares of Emergent BioSolutions fell past 5% in recent trading.Price: 9.33, Change: -0.55, Percent Change: -5.57","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4583":"猴痘概念","EBS":"Emergent Biosolutions"},"translate_title":"Emergent获得与BARDA的埃博拉治疗合同选项","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":0.9},"content_text":"Emergent BioSolutions (EBS) said Monday that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at about $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga.Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus.BARDA is part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.The option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga, with a maximum value of $704 million, the company said.Shares of Emergent BioSolutions fell past 5% in recent trading.Price: 9.33, Change: -0.55, Percent Change: -5.57","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}